|
Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical
company focused on the development and commercialization of drug-products
utilizing an innovative active transdermal drug delivery technology. Our current
proprietary drug-product development programs include
ViaDerm-hPTH (1-34), a transdermal hPTH (1-34) product to treat
osteoporosis, undergoing Phase 2B clinical trials, which is developed in
collaboration with Eli Lilly, and two additional peptides currently in Phase 1.
TransPharma’s drug-product development activities utilize our well-proven
RF-MicroChannel Technology. Our RF-MicroChannel
technology enables the creation of an array of microscopic pores through the
very outer skin surface, allowing the delivery of therapeutic doses of a wide
portfolio of drugs, including biologics, our main area of focus. TransPharma’s
implementation of the RF-MicroChannel Technology is the
ViaDerm delivery system. Intended for home
use, the ViaDerm delivery system consists of a reusable, handheld, low-cost
device and a disposable patch containing a
drug.
TransPharma’s goal is to develop multiple drug-products through
strategic partnerships with leading
pharmaceutical companies and through independent product development. We believe
that combining partnered and proprietary product development ensures
capitalizing of both the promise of our technology and our growing capabilities.
| 
